- Report
- December 2024
- 150 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- July 2024
- 202 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- June 2025
- 364 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 281 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1120EUR$1,250USD£954GBP
- Report
- December 2024
- 84 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- April 2025
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- January 2025
- 200 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- November 2018
- 147 Pages
Global
From €2463EUR$2,750USD£2,100GBP
- Report
- May 2024
- 139 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- October 2023
- 145 Pages
Global
From €2821EUR$3,150USD£2,405GBP
- Report
- October 2023
- 145 Pages
Global
From €2821EUR$3,150USD£2,405GBP
- Report
- December 2023
- 168 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- February 2024
- 168 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Report
- July 2023
- 135 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- July 2023
- 67 Pages
Global
From €3538EUR$3,950USD£3,016GBP
- Report
- November 2023
- 189 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- February 2024
- 112 Pages
Global
From €4255EUR$4,750USD£3,627GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more